ratiopharm GmbH Patent applications |
Patent application number | Title | Published |
20160120869 | SOLID PHARMACEUTICAL DOSAGE FORM - The present invention relates to a solid pharmaceutical dosage from comprising ticagrelor and ASA as pharmaceutically active agents, to a package for storing the solid pharmaceutical dosage form and to a solid pharmaceutical dosage form for the use in the treatment of certain diseases. | 05-05-2016 |
20160030353 | SOLID PHARMACEUTICAL DOSAGE FORM OF DOLUTEGRAVIR - The present invention relates to a solid pharmaceutical dosage form comprising dolutegravir, a method of its preparation and its use in the treatment of an HIV infection. | 02-04-2016 |
20150232457 | CRYSTALLINE FORMS OF AFATINIB DI-MALEATE - Crystalline forms of Afatinib di-maleate are described in the present application and processes for their preparation. The present invention also includes pharmaceutical compositions of such crystalline forms of Afatinib di-maleate, methods of their preparation and the use thereof hi the treatment of a patient in need thereof. The present invention also describes preparing Afatinib free base and salts of Afatinib, other than Afatibin di-maleate, and solid forms thereof. | 08-20-2015 |
20150152044 | DESFESOTERODINE SALTS - The invention relates to substantially pure Desfesoterodine salts, Desfesoterodine salts, solid state forms thereof and pharmaceutical compositions comprising one or more of the Desfesoterodine salts and/or solid state forms thereof. | 06-04-2015 |
20150038491 | SOLID IVABRADINE-CONTAINING COMPOSITION - The present invention relates to a solid composition containing ivabradine or a pharmaceutically acceptable salt thereof. Further, the invention relates to a method for the preparation of such a composition as well as a pharmaceutical product comprising such a composition. | 02-05-2015 |
20140357860 | SALT OF IVABRADINE WITH ADIPIC ACID - The present invention relates to pharmaceutical compositions with delayed release which contain ivabradine adipate as active substance. The present invention furthermore relates to processes for the preparation of this composition and certain salts of ivabradine. | 12-04-2014 |
20140249098 | Pharmaceutical Composition Comprising Dapagliflozin and Cyclodextrin - The present invention relates to pharmaceutical compositions comprising dapagliflozin and cyclodextrin, preferably (2-hydroxy)propyl-b-cyclodextrin or γ-cyclodextrin, preferably as inclusion complex. The invention further relates to a process for producing said pharmaceutical compositions. Finally, the invention relates to the use of cyclodextrin for producing dapagliflozin-containing dosage forms and to methods of purification of dapagliflozin. | 09-04-2014 |
20140147505 | SOLID PHARMACEUTICAL DOSAGE FORM OF TICAGRELOR - The present invention relates to a solid pharmaceutical dosage form comprising ticagrelor as pharmaceutically active ingredient, to certain particles of ticagrelor and to processes of preparing the same. | 05-29-2014 |
20140094478 | COMPOSITION AND TABLET COMPRISING RALTEGRAVIR - The present invention relates to a composition and tablet comprising raltegravir and to a process for the preparation of such tablet. | 04-03-2014 |
20140088107 | OPHTHALMIC PREPARATION COMPRISING A PGF2ALPHA ANALOGUE - The present invention relates to an aqueous ophthalmic preparation comprising a PGF2α analogue and at least one polyvinyl alcohol and the use thereof for the treatment of glaucoma and ocular hypertension. | 03-27-2014 |
20140072526 | METHOD FOR THE PRODUCTION OF ADSORBATES OF A RASAGILINE SALT HAVING A WATER-SOLUBLE ADJUVANT - The present invention relates to an adsorbate of a pharmaceutically compatible rasagiline salt comprising at least one pharmaceutically compatible adjuvant, wherein the at least one pharmaceutically compatible adjuvant is a water-soluble, organic solvent and the rasagiline salt is present in the adsorbate as an amorphous substance. | 03-13-2014 |
20130345310 | SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE - The present invention relates to a solid composition containing at least one pharmaceutically compatible auxiliary ingredient and rasagiline or a pharmaceutically compatible salt thereof as an active ingredient. The invention further relates to a method for producing said solid composition and to a medicine comprising said solid composition. | 12-26-2013 |
20130344149 | Oral Dosage Forms for Modified Release Comprising Tasocitinib - The invention essentially relates to oral dosage forms comprising a JAK3 inhibitor, preferably tasocitinib, suitable for modified release, and processes of preparing such oral dosage forms. | 12-26-2013 |
20130281944 | TRANSDERMAL THERAPEUTIC SYSTEM (TTS) COMPRISING ROTIGOTINE - The present invention relates to a patch containing the active ingredient rotigotine for the transdermal delivery of the active pharmaceutical agent rotigotine, comprising a backing layer (1), a matrix layer (2) containing the active ingredient, and a removable protective sheet (4) which is intended for removal before the patch is applied to the skin, characterized in that disposed with areal coverage between the matrix layer (2) and the removable protective sheet (4) is an additional interlayer (3). | 10-24-2013 |
20130224294 | DRY PROCESSING OF ATAZANAVIR - The invention relates to dry processes for producing oral dosage forms, more specifically tablets, comprising atazanavir and adhesion enhancers. The invention further relates to compacted intermediates comprising atazanavir and adhesion enhancers. | 08-29-2013 |
20130158008 | SOLID IVABRADINE-CONTAINING COMPOSITION - The present invention relates to a solid composition containing ivabradine or a pharmaceutically acceptable salt thereof. Further, the invention relates to a method for the preparation of such a composition as well as a pharmaceutical product comprising such a composition. | 06-20-2013 |
20130142871 | ORAL DOSAGE FORM OF DEFERASIROX - The invention relates to an oral dosage form containing deferasirox, binder, disintegrant and optionally wicking agent, wherein the introduction of the dosage form into water leads to a suspension wherein the suspended particles have an average particle size (D50) of 20 μm to 120 μm, and also to a method of producing it. | 06-06-2013 |
20130116333 | SOLID TAPENTADOL IN NON-CRYSTALLINE FORM - The invention relates to solid tapentadol in non-crystalline form together with a surface stabiliser in the form of a stable intermediate. In the intermediate of the invention, tapentadol is preferably present in amorphous form or in the form of a solid solution. The invention further relates to methods of producing tapentadol in a solid, non-crystalline form and to pharmaceutical formulations containing solid, non-crystalline tapentadol. | 05-09-2013 |
20130102683 | MELT-GRANULATED FINGOLIMOD - The invention relates to methods including the step of joint melt processing of (i) fingolimod or a pharmaceutically acceptable salt thereof, with (ii) a matrix former into an intermediate, intermediates obtainable in this way, and oral dosage forms, especially tablets, containing the intermediates of the invention. The invention further relates to a method of preparing the dosage forms of the invention, especially tablets. Finally, the invention relates to oral dosage forms for the treatment of multiple sclerosis. | 04-25-2013 |
20130102682 | FINGOLIMOD IN THE FORM OF A SOLID SOLUTION - The invention relates to an intermediate containing fingolimod and matrix material, wherein the fingolimod is present in the matrix material in the form of a solid solution. The invention also relates to granules and pharmaceutical formulations containing fingolimod in the form of a solid solution in matrix material. The subject matter of the invention further relates to methods of preparing a solid solution of fingolimod or of an intermediate, and also granules and pharmaceutical formulations containing fingolimod in the form of a solid solution. | 04-25-2013 |
20130095177 | METHOD OF PREPARING AN ORAL DOSAGE FORM COMPRISING FINGOLIMOD - The present invention relates to a method of preparing an intermediate containing fingolimod, a method of preparing granules containing fingolimod, a method of preparing an oral dosage form containing fingolimod and accordingly intermediates, granules and oral dosage forms obtainable by that method. | 04-18-2013 |
20130084335 | IVABRADINE-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition containing ivabradine or a pharmaceutically acceptable salt thereof. The invention further relates to a method for the preparation of such a composition. | 04-04-2013 |
20130059897 | RAPID RELEASE IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to an irbesartan-containing pharmaceutical composition, in particular a tablet thereof, which comprises the active ingredient, a disintegrant with at least one low-substituted hydroxypropyl cellulose. | 03-07-2013 |
20130035355 | PRASUGREL IN MICRONIZED, CRYSTALLINE FORM AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention relates to Prasugrel or a pharmaceutically acceptable salt thereof, compositions containing said active ingredient as well as pharmaceutical compositions containing said active ingredient or a composition containing said active ingredient. The present invention further relates to methods for the preparation of the novel compositions. | 02-07-2013 |
20130028938 | SOLID PHARMACEUTICAL DOSAGE FORM - The present invention relates to a solid pharmaceutical dosage form comprising ticagrelor as pharmaceutically active ingredient, to certain particles of ticagrelor and to processes of preparing the same. | 01-31-2013 |
20120295916 | ORODISPERSIBLE TABLET CONTAINING COMPACTED SILDENAFIL BASE - The invention relates to a process for the preparation of a pharmaceutical intermediate, comprising the steps of (i) mixing (a-i) sildenafil base, (b-i) wicking agent, (c-i) disintegrant, (d-i) optionally glidant; (ii) compacting the mixture; and (iii) milling the compacted material; and to an intermediate obtainable by that process. In addition, the invention relates to a process for the preparation of an orally dispersible tablet (hereinafter also referred to as an “orodispersible tablet”) comprising the intermediate of the invention, and to orodispersible tablets obtainable by that process. | 11-22-2012 |
20120288712 | ESCITALOPRAM AND SOLID PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention relates to Escitalopram having a small median particle size and a solid pharmaceutical composition comprising the same. | 11-15-2012 |
20120270949 | MELT-GRANULATED CINACALCET - The invention relates to an intermediate obtainable by the melt-extrusion of (i) cinacalcet or a pharmaceutically acceptable salt thereof with (ii) a matrix former, and oral dosage forms, especially tablets containing the intermediates of the invention. The invention further relates to a method of preparing the tablets of the invention. Finally, the invention relates to the use of a matrix former and a wicking agent for preparing cinacalcet formulations which can preferably be administered independently of mealtimes. | 10-25-2012 |
20120258171 | COMPOSITION COMPRISING FESOTERODINE AND FIBER - The invention relates to a pharmaceutical composition containing (a) fesoterodine and/or fesoterodine metabolites and (b) fibers, wherein the weight ratio of components (a):(b) is in the range from 1:50 to 1:2; and oral dosage forms containing the pharmaceutical composition. The invention further relates to dry methods of preparing those dosage forms. | 10-11-2012 |
20120231076 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN - The invention relates to pharmaceutical compositions comprising rivaroxaban, suitable for immediate release, and processes of preparing such compositions, preferably by a melt-granulation process or by a specific direct-compression process. | 09-13-2012 |
20120214820 | ORALLY DISINTEGRATING PHARMACEUTICAL DOSAGE FORM CONTAINING ARIPIPRAZOLE - The present invention relates to an orally disintegrating dosage form containing aripiprazole. The formulation of the invention shows a fast disintegration. | 08-23-2012 |
20120202820 | PHARMACEUTICAL COMPOSITION HAVING THE ACTIVE SUBSTANCES METFORMIN AND SITAGLIPTIN OR VILDAGLIPTIN - The present invention relates to a pharmaceutical composition that comprises the active substance metformin in combination with one of the active substances sitagliptin or vildagliptin. The present invention further relates to a method of production of said pharmaceutical composition. | 08-09-2012 |
20120189694 | CO-PRECIPITATE COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR (PDE-5-INHIBITOR) AND A PHARMACEUTICALLY COMPATIBLE CARRIER, PRODUCTION AND USE THEREOF - The invention relates to a co-precipitate comprising a phosphodiesterase-5 inhibitor (PDE-5-inhibitor) and a pharmaceutically compatible copolymer carrier comprising 2 or more different acrylic acid derivatives, a method for production thereof and a medication comprising the co-precipitate according to the invention, a method for producing said medication and the use of said medication for treating an illness wherein the inhibiting of phosphodiesterase-5 is of therapeutic benefit. | 07-26-2012 |
20120184617 | PROCESS FOR PRODUCING FINGOLIMOD SALTS - The invention relates to a process for producing pharmaceutically acceptable salts of fingolimod (I), comprising the step of reacting N-[1,1-bis hydroxymethyl-3-(4-octyl phenyl)-propyl]-acylamide (II) with an acidic compound. Furthermore, the invention provides different pharmaceutically acceptable salts of fingolimod and a polymorphic form of fingolimod hydrochloride. | 07-19-2012 |
20120128773 | DESFESOTERODINE IN THE FORM OF A TARTARIC ACID SALT - The invention concerns desfesoterodine in the form of a tartaric acid salt, in particular in the polymorphic “R form”, as well as a process for its production. In a second aspect, the invention concerns the desfesoterodine of the invention in a microencapsulated form. | 05-24-2012 |
20120122973 | DRY PROCESSING OF RETIGABINE - The invention relates to dry processes for the production of oral dosage forms, especially tablets, containing retigabine and adhesion promoter. In addition, the invention relates to compacted intermediates containing retigabine and an adhesion promoter. Finally, the invention relates to single-dose and multiple-dose containers, preferably sachets and stick-packs, containing the intermediate of the invention. | 05-17-2012 |
20120071488 | MELTING TABLET CONTAINING A SILDENAFIL SALT - The invention relates to an orodispersible tablet comprising the components pharmaceutically acceptable sildenafil salt (a), polymeric adsorbent (b), in particular cation exchanger resin, sweetener (c), and flavoring (d) and, preferably, mucilage (e) and glidant (f). The invention furthermore relates to a process for the preparation of orodispersible tablets comprising a pharmaceutically acceptable sildenafil salt and to the use of a combination of cation exchanger resin and mucilage for masking the flavor of medicaments for treating erectile dysfunction | 03-22-2012 |
20120058183 | RETIGABINE TABLETS, PREFERABLY HAVING MODIFIED RELEASE - The invention relates to tablets, especially tablets with modified release, containing (a) retigabine and a combination of (b) water-soluble excipient and (c) non-water-soluble excipient; and a process for producing them. | 03-08-2012 |
20120022087 | AMORPHOUS AMBRISENTAN - The invention relates to amorphous ambrisentan, preferably together with a surface stabiliser in the form of a stable intermediate. The invention further relates to methods of producing stable amorphous ambrisentan and pharmaceutical formulations containing stable amorphous ambrisentan. | 01-26-2012 |
20120015965 | PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY] PHENYL]-6-[5[[[2-(METHYLSULFONYL) ETHYL]AMINO]METHYL]-2-FURYL]-4- QUINAZOLINAMINE - The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition. | 01-19-2012 |
20120009258 | COMPACTED CINACALCET - The invention relates to an intermediate, obtainable by jointly compacting (i) crystalline cinacalcet or a pharmaceutically acceptable salt thereof, with (ii) a hydrophilising agent, and also tablets containing the intermediates of the invention. The invention further relates to cinacalcet tablets with a bimodal pore size distribution and a method of preparing the tablets of the invention. Finally, the invention relates to the use of a pH adjuster for preparing cinacalcet formulations which can preferably be administered independently of mealtimes. | 01-12-2012 |
20110313050 | SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE - The present invention relates to a solid composition containing at least one pharmaceutically compatible auxiliary ingredient and rasagiline or a pharmaceutically compatible salt thereof as an active ingredient. The invention further relates to a method for producing said solid composition and to a medicine comprising said solid composition. | 12-22-2011 |
20110305762 | PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-6-[5[[[2-(METHYLSULFONYL)E- THYL]AMINO]METHYL]-2-FURYL]-4- QUINAZOLINAMINE - The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition. | 12-15-2011 |
20110300214 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and processes of preparing such compositions. In a second aspect, the present invention relates to a preferred pellet-layering process for preparing such compositions. | 12-08-2011 |
20110295005 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES - The present invention relates to a process for preparing pyrimidine derivatives of the formula V, in particular as intermediates useful for preparing pyrimidine derivatives of a class that is effective at inhibiting the biosynthesis of cholesterol in humans, such as HMG-CoA reductase inhibitors, e.g. rosuvastatin. | 12-01-2011 |
20110293717 | COMPACTED MOXIFLOXACIN - The invention relates to a process for the preparation of tablets containing moxifloxacin, comprising the steps of (i) providing moxifloxacin, pharmaceutically acceptable salts, solvates or hydrates thereof, optionally mixed with one or more pharmaceutical excipients; (ii) compacting it into a slug; (iii) granulating the slug; and (iv) compressing the resulting granules into tablets; and also tablets, granules and compacted material containing compacted moxifloxacin. | 12-01-2011 |
20110281912 | ORAL DISPERSIBLE TABLET - The present invention relates to an oral dispersible tablet comprising at least one filler selected from sugars and sugar alcohols, and microcrystalline cellulose. | 11-17-2011 |
20110189279 | PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE PROPERTIES COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions with modified release properties comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and process of preparing such compositions. | 08-04-2011 |
20110189121 | BITABLETS COMPRISING COMPACTED POLYALLYLAMINE POLYMER AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to a method for producing tablets comprising a polyallylamine polymer, comprising the steps (i) preparation of a polyallylamine polymer or pharmaceutically compatible salts thereof, optionally in a mixture with one or more pharmaceutical excipients; (ii) compaction to give a slug; (iii) granulation of the slug; and (iv) compression of the resulting granules to give tablets; and also to tablets, sachets and slugs comprising a compacted polyallylamine polymer. In addition, the invention relates to tablets comprising a polyallylamine polymer, in particular Sevelamer, with a bimodal pore size distribution. | 08-04-2011 |
20110165235 | DIRECTLY PRESSED ALISKIREN TABLETS - The invention relates to pharmaceutical compositions which contain the active agent Aliskiren and are suitable for the production of tablets by dry pressing, so that prior wet granulation can be obviated. The invention also relates to tablets which can be obtained by dry pressing of these pharmaceutical compositions and to a method for producing these tablets. The invention furthermore relates to the use of the novel pharmaceutical compositions and tablets for treating hypertension and illnesses associated therewith. | 07-07-2011 |
20110065920 | PROCESS FOR PREPARING PENTANOIC DIACID DERIVATIVES - The present invention relates to a process for preparing pentanoic diacid derivatives useful for preparing pyrimidine derivatives, in particular as intermediates useful for preparing pyrimidine derivatives of a class that is effective at inhibiting the biosynthesis of cholesterol in humans, such as HMG-CoA reductase inhibitors, e.g. rosuvastatin. | 03-17-2011 |
20110034703 | CRYSTAL FORMS OF N-[2-(DIETHYLAMINO)ETHYL]-5-[(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE- NE)METHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE AND METHODS FOR THEIR PREPARATION - The present invention relates to novel crystal forms of Sunitinib and methods for their preparation. | 02-10-2011 |
20110008428 | SOLID PHARMACEUTICAL COMPOSITION COMPRISING A NON-PEPTIDE ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC - The present invention relates to a solid pharmaceutical composition comprising at least two layers, wherein the first layer contains a non-peptide angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof in a dissolving matrix and the second layer contains a diuretic or a pharmaceutically acceptable salt thereof. The invention also provides methods for the production of said pharmaceutical compositions. | 01-13-2011 |
20100323017 | Escitalopram and Solid Pharmaceutical Composition Comprising the Same - The present invention relates to Escitalopram having a small median particle size and a solid pharmaceutical composition comprising the same. | 12-23-2010 |
20100310668 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-[2-(DIETHYLAMINO)ETHYL]-5-[(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE- NE)METHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE - The present invention relates to a pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient. | 12-09-2010 |
20100291207 | PHARMACEUTICAL FORMULATION COMPRISING EZETIMIBE - The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 μm to 35 μm and d(0.5) of 3 μm to 20 μm, as well as methods for preparing said formulations. | 11-18-2010 |
20100234636 | Novel Salts of the Active Substance Rasagiline - The invention relates to novel salts of the active substance rasagiline. The salts show excellent processability even after prolonged storage and an excellent storage stability usually superior to known salts after being processed into tablets. | 09-16-2010 |
20100217008 | PROCESS FOR THE PREPARATION OF VALSARTAN AND INTERMEDIATE PRODUCTS - The present invention relates to a new method for the production of valsartan, a valine derivative having the chemical N name is (S)—N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2′-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]amine, and pharmacologically acceptable salts thereof. Furthermore the invention relates to new intermediate compounds which are suitable for the production of valsartan and new methods for the production of intermediate compounds which are suitable for the production of valsartan. | 08-26-2010 |
20100179159 | METHOD FOR THE PRODUCTION OF A MEDICAMENT CONTAINING TADALAFIL - The invention relates to a method for producing a medicament containing tadalafil. In said method, tadalafil is mixed with suitable adjuvants and is heated to a temperature of about 100° C. to about 200° C., preferably about 150° C. to about 200° C., especially about 200° C. | 07-15-2010 |
20100159003 | PROCESS FOR THE PREPARATION OF A MEDICAMENT COMPRISING VARDENAFIL HYDROCHLORIDE TRIHYDRATE - The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20° C. to approx. 45° C. | 06-24-2010 |
20100151012 | STABILISED PHARMACEUTICAL COMPOSITION CONTAINING PREGABALINE - Solid pharmaceutical composition containing: (a) pregabaline as active principle and (b) one or several pharmaceutical auxiliary agents, the composition being essentially free from saccharides and comprising no further amino acids, apart from pregabaline. | 06-17-2010 |
20100137447 | METHOD FOR THE PRODUCTION OF ADSORBATES OF A RASAGILINE SALT HAVING A WATER-SOLUBLE ADJUVANT - The present invention relates to an adsorbate of a pharmaceutically compatible rasagiline salt comprising at least one pharmaceutically compatible adjuvant, wherein the at least one pharmaceutically compatible adjuvant is a water-soluble, organic solvent and the rasagiline salt is present in the adsorbate as an amorphous substance. | 06-03-2010 |
20100104640 | PHARMACEUTICAL COMPOSITIONS COMPRISING IRBESARTAN - The present invention relates to a pharmaceutical composition comprising irbesartan. | 04-29-2010 |
20090220597 | RAPID RELEASE IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to an irbesartan-containing pharmaceutical composition, in particular a tablet thereof, which comprises the active ingredient, a disintegrant with at least one low-substituted hydroxypropyl cellulose. | 09-03-2009 |
20090149677 | Stereoselective Method for the Production of (R)-Dimepranol - The present invention relates to processes for preparing a compound of the general formula (Ia) | 06-11-2009 |
20090111994 | Method for The Production of Losartan - The present invention relates to a novel process for preparing losartan, an imidazole derivative with the chemical name 2-n-butyl-4-chloro-5-hydroxymethyl-1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-]methyl}imidazole, and pharmacologically active salts thereof. The invention further relates to novel intermediates which are suitable for preparing losartan and to novel processes for preparing intermediate compounds which are suitable for preparing losartan. | 04-30-2009 |
20080319195 | Enantioselective Preparation of Benzimidazole Derivatives and Their Salts - The invention relates to a new process for preparing benzimidazole derivatives having a chiral sulfoxide group in enantiomerically pure form or in a form in which one of the two enantiomers is present in an increased quantity over the other enantiomer. The invention likewise relates to a process for preparing the salts of the individual enantiomers of the benzimidazole derivatives with a chiral sulfoxide group. The invention relates in particular to a process for preparing the S-enantiomer of omeprazole (also known as esomeprazole) and the salts thereof, more particularly the zinc salt of the S-enantiomer of omeprazole. In the new process a prochiral sulfide is oxidized in an organic solvent with an oxidizing agent in the presence of a titanium(IV) complex. | 12-25-2008 |